
News|Articles|September 1, 2003
Fondaparinux effective and well-tolerated for prevention of VTE in acutely ill patients
Fondaparinux (Arixtra, Organon/Sanofi-Synthelabo) given once daily significantly reduces the risk of venous thromboembolism (VTE) in acutely ill, hospitalized patients, according to data from the Arixtra for ThromboEmbolism prevention in a Medical Indications Study (ARTEMIS).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
TrumpRx launches; some experts question its long-term value
3
PBM reform. It has finally happened
4
What exactly is managed care today?
5























